The basic short-circuit that prevents things from moving forward is the fact that, even if Bolivia and Biolyse Pharma had succeeded in going through all the required hoops, Canada refused to include it in schedule 1, leaving no other recourse.
What was absolutely deplorable in my view, was when Canada, in December 2020, took a position at the World Trade Organization, the WTO, by simply saying that if no one had called upon the CAMR, that simply showed that there was no need to work toward an exemption from certain provisions of the TRIPS Agreement, or from some aspects of intellectual property rights pertaining to trade.
This declaration was quite simply dishonest, to put it mildly. I don't know who, in the group working on international trade patents, decided to take that position, but it was simply nonsense.